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STUDY PROTOCOL Open Access
Circulating tumor DNA guided adjuvant
chemotherapy in stage II colon cancer
(MEDOCC-CrEATE): study protocol for a trial
within a cohort study
S. J. Schraa1†, K. L. van Rooijen1†, D. E. W. van der Kruijssen1, C. Rubio Alarcón2, J. Phallen3, M. Sausen4,
J. Simmons4, V. M. H. Coupé5, W. M. U. van Grevenstein6, S. Elias7, H. M. Verkooijen7, M. M. Laclé8, L. J. W. Bosch2,
D. van den Broek9, G. A. Meijer2, V. E. Velculescu3, R. J. A. Fijneman2†, G. R. Vink1†, M. Koopman1*† and And on
behalf of the PLCRC-MEDOCC group
Abstract
Background: Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon
cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form
adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for MRD and has high
predictive value for recurrent disease. The MEDOCC-CrEATE trial investigates how many stage II CC patients with
detectable ctDNA after surgery will accept ACT and whether ACT reduces the risk of recurrence in these patients.
Methods/design: MEDOCC-CrEATE follows the ‘trial within cohorts’ (TwiCs) design. Patients with colorectal cancer
(CRC) are included in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) and give informed consent for
collection of clinical data, tissue and blood samples, and consent for future randomization. MEDOCC-CrEATE is a
subcohort within PLCRC consisting of 1320 stage II CC patients without indication for ACT according to current
guidelines, who are randomized 1:1 into an experimental and a control arm.
In the experimental arm, post-surgery blood samples and tissue are analyzed for tissue-informed detection of
plasma ctDNA, using the PGDx elio™ platform. Patients with detectable ctDNA will be offered ACT consisting of 8
cycles of capecitabine plus oxaliplatin while patients without detectable ctDNA and patients in the control group
will standard follow-up according to guideline.
The primary endpoint is the proportion of patients receiving ACT when ctDNA is detectable after resection. The
main secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR, disease free survival, overall
survival, time to recurrence, quality of life and cost-effectiveness. Data will be analyzed by intention to treat.
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Discussion: The MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC patients to be treated
with ACT guided by ctDNA biomarker testing and whether ACT will prevent recurrences in a high-risk population.
Use of the TwiCs design provides the opportunity to randomize patients before ctDNA measurement, avoiding
ethical dilemmas of ctDNA status disclosure in the control group.
Trial registration: Netherlands Trial Register: NL6281/NTR6455. Registered 18 May 2017, https://www.trialregister.nl/
trial/6281
Keywords: Colon cancer, Circulating tumor DNA, ctDNA, Adjuvant chemotherapy, TwiCs
Background
In patients with stage II colon cancer (CC) the recur-
rence rate (RR) after surgery is approximately 15–20%
[1]. Disease management after surgical resection in stage
II CC is still under debate, because the overall survival
(OS) benefit of adjuvant chemotherapy (ACT) in this
group of patients varies between 2 and 5% only [2, 3].
Moreover, offering ACT in a low-risk population in-
duces an important amount of overtreatment with un-
necessary, but sometimes severe toxicity, and costs.
Several prognostic characteristics of stage II CC have
been identified to provide better selection of patients
that might benefit from ACT. Patients with presence of
at least one of the following characteristics are classified
as being at high risk of disease recurrence: poorly differ-
entiated histology, pT4 lesions, inadequately (less than
12) sampled lymph nodes, lymphovascular or perineural
invasion or tumor presentation with perforation or ob-
struction [4].
In contrast, patients with a deficient mismatch re-
pair (dMMR) status in stage II CC have a low risk of
recurrence and ACT is not considered beneficial, irre-
spective of the presence of other risk factors [5, 6].
Other known prognostic factors in CC, like gene ex-
pression profiles or BRAF (V600E) and RAS muta-
tions, have been investigated but do not adequately
identify the patients that will benefit from ACT [7–9].
Despite the definition of high- and low risk subgroups
of stage II CC patients, retrospective analyses demon-
strated that improved survival after administration of
ACT was not observed in high risk patients, or exclusively
in patients with a pT4 tumor [10–12]. Therefore in the
Netherlands, ACT is currently only recommended in stage
II CC patients with a pT4 tumor without dMMR.
Unfortunately, also pT4 is not an absolute predictor
for disease recurrence in stage II patients. In a retro-
spective analysis of 995 stage II CC patients with pT4
tumors, the 3-year disease-specific survival rate after
surgery was 91% in patients who received ACT and
73% in patients who did not receive ACT, which
means that 73% of these patients are exposed to ACT
unnecessarily [12]. Considering non-pT4 stage II pa-
tients, a population registry analysis of 40,338 patients
showed that in this group 12.5% of patients suffered
from recurrences [13]. These data demonstrate that
using pT4 as a prognostic factor results in significant
under- and overtreatment.
Minimal residual disease (MRD) is defined as the pres-
ence of tumor cells in the blood, bone marrow or lymph
nodes not detected by conventional staging procedures
[14]. Patients who have MRD after surgery are not com-
pletely cured and therefore at high risk of developing
disease recurrence. Development of a highly specific and
sensitive (bio)marker test indicative for MRD would
allow identification of the subset of patients likely to ex-
perience recurrence of disease, thereby improving the se-
lection of patients who may benefit from adjuvant
treatment. In adjuvant trials, this would solve problems
of high numbers needed for inclusion and dilution of ef-
fectiveness of adjuvant treatment by inclusion of many
already cured participants [15].
Cell-free circulating tumor DNA (ctDNA) has a strong
potential for being this sensitive, and yet specific bio-
marker. ctDNA consists of small fragments (usually
150–200 bp) of tumor-derived DNA containing tumor-
specific mutations which can be detected in liquid biop-
sies such as blood samples [16–18]. Because of the short
half-life of ctDNA (estimates ranging from 15 to 120
min) the presence of ctDNA in blood samples taken sev-
eral days after surgery presumably reflects a state of
MRD [19–21]. Patients with MRD have the highest risk
for disease recurrence.
Recently, the presence of ctDNA after tumor resec-
tion demonstrated a very strong prognostic value for
disease recurrence in stage II CC, with a 2-years RR
of 79.0% versus 9.8% in patients with and without de-
tectable ctDNA after surgery respectively [21]. In this
study the univariate prognostic value of ctDNA was much
higher than that of pT4 status (hazard ratio of 14 versus 2.6,
respectively). There are several ongoing trials that use
ctDNA in prognostication (NCT03637686, NCT03737539,
NCT03416478, NCT03312374, NCT02842203, NCT0361
5170) and treatment (NCT03748680, ACTRN12615000381
583, NRG-GI 005) of non-metastatic CC, but to date there
are no results available of randomized controlled trials
(RCTs) that use ctDNA for selection of ACT treatment.
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The accumulating evidence for the strong prognostic
value of ctDNA raises an important ethical dilemma for
randomization of patients when designing a conven-
tional RCT, in which patients with detectable ctDNA are
randomized into ACT treatment or standard of care
follow-up while disclosing ctDNA status to the control
group. Indeed, the knowledge of having a very high
chance of disease recurrence will be a big burden for pa-
tients with detectable ctDNA in the control group and
their caregivers as they are not being offered any add-
itional therapy. This warrants an innovative trial design
different from the conventional RCT, like the ‘Trial
within Cohorts’ (TwiCs) design [22–25]. The TwiCs de-
sign enables an experimental group in which ctDNA sta-
tus is disclosed and a control group that is unaware of
their ctDNA status.
The MEDOCC-CrEATE trial is designed as a multi-
center TwiCs study with two parallel groups in which
we will investigate whether stage II CC patients with de-
tectable ctDNA after resection are willing to receive




This study investigates the willingness of patients to re-
ceive ACT after detection of ctDNA post-surgery and
the effect of ctDNA-guided ACT on the RR in stage II
CC patients.
Study design
The MEDOCC-CrEATE trial follows the TwiCs design
and is performed within the Prospective Dutch ColoRec-
tal Cancer cohort (PLCRC; www.PLCRC.nl) [26]. PLCR
C is set up by the Dutch Colorectal Cancer Group
(DCCG) and collects clinical data and Patient Reported
Outcome Measures (PROMs) at baseline and at multiple
time points during follow-up (Fig. 1). At enrollment, pa-
tients give informed consent for use of their clinical data
and optionally for receiving quality of life questionnaires,
Fig. 1 Schematic presentation of MEDOCC-CrEATE, using the trial within cohort (TwiCs) design. a PLCRC is a nationwide cohort study in the
Netherlands with inclusion of CRC patients (all stages). By optional informed consent regarding collection of biomaterials and future
randomization, observational as well as interventional trials can be performed within the cohort. b Non-metastatic CRC patients are included in
MEDOCC when the patient signs informed consent for PLCRC including additional blood sampling. Blood samples are withdrawn before
resection, 4–21 days after resection and every 6 months during the first 3 years of follow-up. c Eligible stage II colon cancer patients are
randomized 1:1 following the TwiCs design. In the experimental group informed consent is being asked for immediate ctDNA analysis of the
blood sample obtained after resection. If ctDNA is detectable, patients are offered adjuvant chemotherapy. The control group is not informed
about MEDOCC-CrEATE and will receive standard of care
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collection of biomaterials for research, additional se-
quential blood sampling and for being approached for
future studies conducted within the infrastructure of
the cohort, either in accordance with the TwiCs de-
sign or not.
Patient selection and recruitment
Patients will be recruited in both academic and non-
academic hospitals in the Netherlands that are partici-
pating in PLCRC. Non-metastatic colorectal cancer
(CRC) patients that give informed consent for PLCRC
including consent for additional blood sampling at en-
rollment, will be included in the observational PLCRC
substudy MEDOCC (Molecular Early Detection of Colon
Cancer) before surgery. The participants are eligible for
the current MEDOCC-CrEATE trial if they meet the fol-
lowing criteria after surgery: (1) histopathological con-
firmed and radically resected stage II CC; (2) age ≥ 18
years; (3) informed consent for PLCRC and MEDOCC
including consent for randomization in future trials and
use of tissue; (4) physical condition allows treatment
with combination chemotherapy consisting of a fluoro-
pyrimidine and oxaliplatin; and (5) no indication for
ACT according to the treating physician and/or multi-
disciplinary board. Patients who are pregnant, have had
another malignancy in the previous 5 years, except for
carcinoma in situ, or patients with contra-indications for
fluoropyrimidines and/or oxaliplatin will be excluded.
Currently the Dutch guidelines recommend ACT for
patients with pT4 tumors. However, there is large age-
and hospital dependent variation in administration of
ACT in this group and in clinical practice not all stage II
patients with pT4 tumors will be offered ACT [27].
Therefore, we will include eligible patients with pT4 tu-
mors without a recommendation for ACT according to
their treating physician and use pT4 status as a stratifi-
cation factor.
Blood sample collection
Blood samples are collected before and 4–21 days after
surgery for all patients included in the MEDOCC clinical
study, predominantly comprising stage I, II and III CC
patients (Table 1). Blood samples (two tubes of 10 ml
per timepoint) are collected in Cell free DNA Streck
Blood Collection Tubes for various research purposes,
among which the MEDOCC-CrEATE trial.
Randomization
About 1 week after surgery, when the histopathological
report is finished, MEDOCC patients who are eligible
for MEDOCC-CrEATE will be randomized 1:1 to the
intervention or control arm using SLIM, an online
platform to manage patient inclusion including a
randomization service. The computer generated
randomization schedule is stratified by T-stage and uses
permuted blocks of random sizes. Allocation conceal-
ment will be ensured, as the service will not release the
randomization code. Only patients randomized to the
intervention arm will be informed about MEDOCC-
CrEATE according to the TwiCs design [22].
Experimental arm
After randomization, only patients randomized to the
experimental arm will be asked separate informed
Table 1 Standard Protocol Items for Intervention Trials (SPIRIT): schedule of enrollment, interventions and repeated measurements.
ACT: adjuvant chemotherapy; ctDNA: circulating tumor DNA; QoL: quality of life. * Intervention group only. ** Intervention group
only, if ctDNA is positive
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consent for the immediate analysis of ctDNA status of
the post-surgery sample. A small proportion of patients,
estimated approximately 5–8% will have detectable
ctDNA in their blood. These patients will be offered
ACT. Patients decide whether they accept or refuse this
treatment. Patients without detectable ctDNA will re-
ceive routine standard of care.
ACT will consist of 6 months of capecitabine and oxa-
liplatin (CAPOX) or 6 months of fluorouracil, leucovorin
and oxaliplatin (FOLFOX). Treatment starts preferably
within 8 weeks and not beyond 12 weeks after surgery.
During and after completing ACT routine follow-up
will consist of regular visits at the surgical outpatient de-
partment, blood withdrawals for analysis of carcinoem-
bryonic antigen (CEA) and imaging (standard ultrasound
of the liver) according to current guidelines in the
Netherlands. No additional imaging will be performed to
prevent detection bias.
Control arm
In the control arm, patients will not be informed about
the MEDOCC-CrEATE trial and receive routine follow-
up care consisting of CEA tests every 3 months for the
first 3 years and abdominal ultrasound or CT every 6
months in the first year and once a year afterwards. One
year after surgery a colonoscopy is performed. Post-
surgery blood samples will not be tested for ctDNA im-
mediately, but will be analyzed batch-wise after several
months without result disclosure to patients and their
treating physicians.
Follow-up
Blood samples will be collected at 6-monthly intervals
for the first 3 years after surgery for both patients in the
experimental arm and the control arm conform the
MEDOCC study protocol. These samples will not be an-
alyzed for ctDNA immediately and results will not be
disclosed to patients and treating physicians.
Tumor tissue-informed ctDNA analysis
After surgery the local pathologist will send a formalin-
fixed paraffin-embedded (FFPE) tissue block to the
central laboratory, where DNA will be isolated for fur-
ther analysis.
The post-surgery blood sample is drawn between 4
and 21 days after surgery. The sample is not withdrawn
before day 4 to reduce the risk of false-negative ctDNA
tests due to the relatively large amount of cell free DNA
(cfDNA) released due to cell damage after surgery. The
blood is taken no later than 21 days after surgery to be
able to start chemotherapy within 12 weeks after surgery.
Samples are kept at room temperature and sent by regu-
lar mail to the central laboratory within 1–2 days, where
ctDNA will be isolated for further analysis.
Tumor tissue DNA will be analyzed by targeted next
generation sequencing of a panel of more than 500
genes using the PGDx elio™ tissue complete assay from
Personal Genome Diagnostics (PGDx, Baltimore, MD,
USA). Plasma ctDNA will be analyzed by targeted next
generation sequencing of a panel of more than 30 genes
using the PGDx elio™ plasma resolve assay from PGDx
(Baltimore, MD, USA). Both panels include the most
commonly mutated genes in CC, including APC, TP53,
KRAS and BRAF. Tumor tissue DNA mutations are used
as input information for plasma ctDNA mutation calling,
thereby increasing both sensitivity and specificity of the
ctDNA test.
Primary endpoint
The primary endpoint is the proportion of patients start-
ing with ACT after detection of ctDNA in the post-
surgery sample.
Secondary endpoints
The most important secondary endpoint is 2-year RR in
patients with detectable ctDNA in their blood, expressed
as the proportion of patients that experience a recur-
rence within 2 years after surgery. Detection of recur-
rences (in months after surgery) will occur by standard
follow-up investigations including 3–6 monthly blood
sampling of tumor marker CEA and 6 monthly imaging
with ultrasound liver or CT abdomen and when indi-
cated by symptoms. Radiological and/or histopatho-
logical evidence is used to confirm the recurrence; the
date of the said investigation is considered the date of
recurrence.
Data about follow-up, recurrences and survival are
routinely collected within PLCRC using the Netherlands
Cancer Registry (NCR), managed by the Netherlands
Comprehensive Cancer Organisation (IKNL) to provide
insight in the characteristics and magnitude of cancer in
the Netherlands [28].
Other secondary endpoints include 2-year RR in a
per-protocol analysis, 5-year RR (intention-to-treat
and per-protocol analysis), time to recurrence (TTR),
2- and 5-year disease free survival (DFS) rate, 5- and
7-year disease-related OS rate, 2- and 5-year RR in
patients with undetectable ctDNA after surgery, qual-
ity of life (QoL) and cost-effectiveness of the ctDNA-
guided strategy.
Time-to-event outcomes
OS rate is expressed as proportion of patients that are
alive 5 and 7 years after surgery. DFS rate is expressed as
proportion of patients that did not experience disease re-
currence, a second primary CC or death within 2 and 5
years after surgery. TTR is expressed as time (months)
between surgery and detection of disease recurrence.
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Patients will be censored at the last date of follow-up if a
date of death is not recorded and at the date of death if
the cause of death is not due to CC.
Quality of life
QoL is measured within the cohort at regular intervals
in patients who gave consent to send questionnaires. Na-
tionally and internationally validated questionnaires are
used, among which the European Organisation for Re-
search and Treatment of Cancer Quality of Life Ques-
tionnaire Core 30 and the ColoRectal cancer module
(EORTC-QLQ-C30 and -CR29), the Work Ability Index
(WAI), the Euro Quality of life-5 Dimensions (EQ-5D),
the Multidimensional Fatigue Inventory-20 (MFI-20)
and the Hospital Anxiety and Depression Score (HADS).
Cost-effectiveness of the ctDNA-guided treatment
The cost-effectiveness analysis will be carried out from a
societal perspective, including both direct health care
costs as well as indirect costs from productivity loss. The
health outcome measure in the cost-effectiveness ana-
lysis will be the total quality adjusted life years (QALY)
per group. For analysis of factors related to QALYs
questionnaires are used, provided within PLCRC.
Sample size considerations
The primary endpoint is the proportion of ctDNA posi-
tive patients starting with ACT. However, 2-year RR in
the ctDNA positive patients after surgery is an important
secondary endpoint and the power calculation is per-
formed for this secondary endpoint. We estimate that,
similar to effectiveness in stage III CC patients, ACT in
ctDNA-based high-risk stage II CC patients will lead to
a 30% absolute reduction of recurrences within 2 years
after surgery. In the observational trial 79% of patients
with detectable ctDNA experienced disease recurrence
within 2 years after resection [21].
With a power of 80% and an alpha of 0.05, 30 patients
with detectable ctDNA need to be included in both
arms. Assuming a prevalence of ctDNA after surgery of
5%, and adjustment for loss to follow-up and rejection of
adjuvant therapy in the intervention arm of 10%, a total
sample size of 1320 patients is calculated (660 in each
arm). We expect few patients with detectable ctDNA in
the intervention group to refuse ACT, because patients
are selected upfront for being in a physical condition to
receive ACT and the established prognostic value of de-
tectable ctDNA is high.
We assume that cross-over from the control arm to
the intervention arm will not occur, because only eligible
patients randomly selected in the cohort and allocated
to the intervention arm will be informed about the trial
and have the opportunity for immediate analysis of
ctDNA. Patients in the control group will not be in-
formed about the trial or their ctDNA status.
We assume that 90% of patients in the intervention
arm with detectable ctDNA will be treated with ACT.
The proportion of patients starting with chemotherapy,
the primary endpoint, can in that instance be deter-
mined with a margin of error (width of the 95% confi-
dence interval) of 11%.
We expect to complete recruitment of patients within
2–3 years with more than 20 participating Dutch
hospitals.
Data analysis
Data will be analyzed according to the intention-to-treat
principle for the primary endpoint and the secondary
endpoint of 2-year RR in patients with detectable ctDNA
after surgery. In this analysis we expect to compare 30
patients with detectable ctDNA who received ACT in
the intervention arm with 30 patients with detectable
ctDNA in the control arm, i.e. based on ctDNA analysis
performed retrospectively, at least 3 months after sur-
gery, and not disclosed to patients and treating physi-
cians. The proportion of patients that experience a
recurrence in both arms will be compared by means of a
chi-square test. In addition, for other secondary end-
points and exploratory analyses we will analyze time-to-
event outcomes in patients in both arms with detectable
ctDNA after surgery. Differences in time-to-event out-
comes will be analyzed by standard survival methods,
e.g. Kaplan-Meier curves compared by log-rank tests.
Cox’s proportional hazards models will be used for mul-
tivariable analysis.
Comparison of QoL of the ctDNA positive patients in
both study arms will be done using repeated measure-
ments methods and including ACT as factor. QoL will
also be analyzed for the whole population in both arms
of the study. Treatment differences at each QoL assess-
ment time point will be compared by means of the
Wilcoxon Rank Sum Test.
A lifetime horizon will be applied for the cost-
effectiveness analysis, parametric survival functions will
be used to extrapolate DFS and OS curves beyond 5
years.
Responsibilities
Protocol modifications will be submitted as amendment
to the medical ethical committee by the study coordin-
ator. The local principle investigator of each participat-
ing hospital is responsible for patient inclusion, logistics
of biomaterials to the central laboratory and patient
follow-up. To ensure quality of data, study integrity and
compliance with the protocol and the various applicable
regulations and guidelines, a data monitor of the IKNL
has been appointed to conduct site visits to the
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participating centers and randomly check patient data.
The study coordinator – together with the principle in-
vestigator - will have access to the final dataset and is re-
sponsible for publishing study results. The results will be
submitted to a peer-reviewed journal.
Discussion
MEDOCC-CrEATE is the first clinical trial using the
TwiCs design to investigate ctDNA-guided strategies in
stage II CC, taking an important step towards clinical
implementation of ctDNA in cancer diagnostics and
care.
A few other trials with the aim to reduce recurrences
in CC by use of a ctDNA-guided approach are in prepar-
ation or recently started. The IMPROVE-IT trial, a
Danish study started in October 2018, uses a classical
RCT in stage I and II CRC patients, randomizing be-
tween 6months of ACT or intensified follow-up for 64
patients with detectable ctDNA post-surgery
(NCT03748680). Four hundred fifty stage II CRC pa-
tients are being included in the Australian DYNAMIC
study and randomized 2:1 to be treated according to the
ctDNA result with 3 to 6 months of ACT or according
to standard of care (ACTRN12615000381583). The
COBRA study in the United States and Canada has a
similar RCT approach (NRG-GI 005). Also, several trials
in stage III CRC patients started recently (DYNAMIC
III, ACTRN12617001566325). In the near future these
studies will provide deeper understanding and lead to
implementation of ctDNA-guided strategies in clinical
practice.
In the current era of rapidly emerging new diagnostic
and treatment strategies, the classical RCT is challenged
because of inefficient and therefore time-consuming re-
cruitment of eligible patients. Main reasons for patients
to refrain from participation in RCTs are preference for
one of the treatment arms, anxiety or aversion to
randomization and difficulties understanding the con-
cept of an RCT, resulting in a delay of availability of
potential beneficial treatments [29]. Modern trial designs
are being adopted to avoid this inefficient, time-
consuming and costly way of conducting trials with high
rates of unfinished studies. Therefore, the MEDOCC-
CrEATE trial uses the modern TwiCs design. The TwiCs
design has shown to have a positive impact on trial
efficiency. Also, by enrolling higher proportions of eli-
gible patients generalizability to daily clinical practice
improves [25].
This study design has several strengths. First,
MEDOCC-CrEATE is nested within the large nation-
wide PLCRC cohort study with currently almost 8000
included CRC patients. The infrastructure of this cohort,
in which clinical data and biomaterials are collected after
broad informed consent of participating patients, allows
comprehensive, innovative and efficient research in
CRC. Using this infrastructure, the study can be quickly
implemented in many participating hospitals, saving
costs and complicated logistics. Several studies according
to the TwiCs design are performed within this or com-
parable cohorts. Therefore experience with this trial
design has been gained and this will contribute to execu-
tion of the MEDOCC-CrEATE study [30, 31].
Secondly, a difficult ethical dilemma in an RCT analyz-
ing ctDNA presence post-surgery is avoided by the
TwiCs design. With the current knowledge about the
strong association with recurrent disease, disclosing
ctDNA status to all participants would be a great burden
for patients with detectable ctDNA and their treating
physicians in the control group. Because of ‘disappoint-
ment bias’ in the control group we would expect high
drop-out and contamination due to cross-over when a
classical RCT design would be applied, making accrual
and interpretation of results unfeasible [32]. In this
TwiCs study, all participants already have blood with-
drawn after surgery for research purposes, and only the
eligible patients allocated to the intervention arm will
have the opportunity to obtain a ctDNA test result and
ACT if ctDNA is detected. Patients in the control arm,
treated according to current guidelines, will not be in-
formed about randomization and their blood samples
will be analyzed at a later point in time beyond the win-
dow of ACT treatment.
This study has also potential limitations and chal-
lenges. The TwiCs design is potentially susceptible to
low statistical power and internal validity biases. Levels
of participant’s eligibility and consent should be substan-
tial to achieve valid and reliable results, and measure-
ments taken in the control group should be sufficient for
adequate comparisons to be made [33]. Therefore the
TwiCs design is not appropriate for every experimental
intervention. In case of the MEDOCC-CrEATE study,
we argue that eligibility and also consent will be substan-
tial because of the high incidence of CC, the large cohort
with high inclusion rates and the assumption that eli-
gible patients in the intervention group are willing to
accept ACT because of the very strong association of the
presence of ctDNA with recurrent disease.
Another limitation is the small sample size for primary
outcome analysis. Eventually only 30 patients in both
arms of the trial are expected to have detectable ctDNA
after surgery. Based on previous data, 80% relapses are
expected within 2 years, and with a high event rate small
numbers are sufficient [21].
We recommend a 6-month duration of ACT consist-
ing of capecitabine and oxaliplatin (CAPOX) or
fluorouracil, leucovorin and oxaliplatin (FOLFOX) for
patients with detectable ctDNA after surgery. The first
adjuvant CC trials investigating the combination of a
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fluoropyrimidine and oxaliplatin reported results for 6
month duration of ACT [34]. In 2018 the IDEA trial
found a large reduction in toxicity for 3 months treat-
ment compared to 6 months treatment. Although this
trial could not confirm non-inferiority for 3 months
treatment for all patients treated with CAPOX or FOL-
FOX in stage III CRC, the small difference limits clinical
relevance. Besides, it did show non-inferiority of the
shorter regimen in patients treated with CAPOX. Conse-
quently, Dutch guidelines recommend 3months of ACT
for CC since 2019. However, among patients with
highest risk of recurrence (T4, N2, or both) superiority
of 6-month duration of therapy was found. Additional
IDEA-FRANCE results, presented at the ESMO
Congress 2019, showed the worst prognosis for ctDNA
positive patients who only received 3 months of ACT
[35]. Therefore in this study, we recommend 6-months
ACT for patients with a very high risk of disease recur-
rence due to the presence of ctDNA after surgery.
Liquid biopsy ctDNA detection has become a promis-
ing technology with multiple putative clinical applica-
tions, including its potential use as a biomarker for early
diagnosis, prognosis, prediction, and monitoring of treat-
ment response [36]. Driven by the excitement of its pos-
sibilities, the field of technology of ctDNA detection and
analysis is rapidly evolving. Yet, the clinical utility of
ctDNA testing still needs to be proven. When to apply
what technology to address which unmet clinical need is
a key question that remains to be addressed [18].
Applying ctDNA detection as a biomarker for MRD is
a challenging task. Biologically, only a very low amount
of ctDNA is present in post-surgery patients with MRD.
Stochastically, by looking at mutations in a panel of
genes chances increase that in a given blood sample at
least in one of the genes a mutation can be reliably de-
tected. Test sensitivity can be further increased by mak-
ing use of DNA mutation information from tumor
tissue, because the stringency in the calling of plasma
ctDNA mutations can be reduced once you know what
mutations to look for. Tissue-informed ctDNA analysis
also increases the ctDNA test specificity. Recent obser-
vations showed that ctDNA mutation detection can be
confounded by mutations that are present in clonal
hematopoiesis, including mutations in genes that are
commonly affected in CC such as TP53 [37]. These con-
founding mutations can be filtered by applying tissue-
informed ctDNA analyses. As such, technically the
MEDOCC-CrEATE trial makes use of a ctDNA test that
is well-suited for MRD detection [38]. Clinically, how-
ever, the MEDOCC-CrEATE trial needs to resolve
whether a positive ctDNA test also allows to select for
patients who truly benefit from ACT treatment, a re-
quirement for clinical implementation. To further sup-
port clinical implementation of ctDNA analyses in the
Netherlands, the Dutch COIN initiative aims to provide
a validation framework for clinical implementation of
ctDNA analyses in the Netherlands (ZonMW project
number 848101011).
In conclusion, the MEDOCC-CrEATE study is the
first study using the modern and innovative TwiCs de-
sign to study ctDNA-guided administration of ACT in
stage II CC patients. The study aims to answer the im-
portant clinical question whether ctDNA has prognostic
as well as predictive value. If this study demonstrates a
significant and substantial difference in disease recur-
rence in the intervention group compared to the control
group, ctDNA analysis and ctDNA-guided treatment
should be implemented into clinical practice to improve
the prognosis of stage II CC patients.
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